Answers are grounded in this paper and cite their sources.
The development of biological products is associated with high costs [2, 3]. This, together with the increase in the use of biotechnology-derived medicines, results in high annual treatment costs. In 2008, sales of biopharmaceutical medicines in Europe reached Euros 60 billion [4]. In 2009, sales in the US amounted to almost US$70 billion (around Euros 52 billion) [5]. The considerable cost of biologicals places an additional burden on healthcare systems, forcing cost-cutting measures in other areas of healthcare delivery.
No takes yet. Share an insight, caveat, or question.
Robert Haustein (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: